EU trial rules stall research

European clinical trial guidelines meant to make trials safer and more efficient are actually slowing down studies that could help patients, and even dissuading researchers from launching trials at all, according to an opinion published online today (November 16) in PLoS Medicine. Image: Wikimedia commons, S. Solberg J.The European Union's Clinical Trials Directive, adopted in 2004, says that trials evaluating investigational medicinal products should follow Good Clinical Practice (GCP), an in

Written byJef Akst

| 2 min read

Save for Later

Image: Wikimedia commons,
S. Solberg J.

The European Union's Clinical Trials Directive, adopted in 2004, says that trials evaluating investigational medicinal products should follow Good Clinical Practice (GCP), an international quality standard for human clinical trials. According to linkurl:Alex McMahon;http://www.fom.gla.ac.uk/research/profile.php?id=4cdbe7ed8b95 of the University of Glasgow in Scotland and his colleagues, who wrote the opinion piece, the stringent definition of GCP employed in the Directive makes sense for trials sponsored by biopharma companies, which are generally developing new medicines, but not for trials run by academic medical centers, which more often are studying already-licensed drugs in order to fine-tune their use in the clinic. Although the regulatory suggestions outlined in the Directive are not legally binding in most EU countries, the authors write, academic centers and regulatory agencies are needlessly enforcing them, and this over-interpretation of the rules is dramatically slowing academic clinical work. "Since the legislation, the approval [process for clinical trials] has magnified several-fold in terms of [effort] and length of time," said linkurl:Morris Brown,;http://www.med.cam.ac.uk/html/PI/Brown/Research%20Profile.html a professor of clinical pharmacology at the University of Cambridge, UK, who wasn't an author on the opinion. The Directive "makes it very difficult for anyone but the most determined person to get the research started." Getting a trial going now involves approval not just from an ethics committee, but often from "research and development" departments cropping up at universities, said Brown, who linkurl:wrote about the issue;http://www.bmj.com/cgi/content/extract/337/oct16_2/a1732 last year in the British Medical Journal. He added that the ethics submission has grown from just a few pages to an 80-page document, requiring extensive detail on such issues as informed consent, reporting of adverse events, and national inspection of trials. While these issues are important, they were satisfied under the old system in a much more efficient manner, he said. The increased paperwork is dragging out the time needed to get trial protocols approved, he said. While it used to take just a few months to get a clinical trial up and running, it can now take more than a year. Furthermore, he added, "younger investigators are put off from even starting on the project." According to McMahon and his colleagues, European regulators need to recognize this problem and adjust accordingly. In addition, they write, "other parts of the world should learn a lesson from the misguided trial regulation that have been created in Europe."
**__Related stories:__***linkurl:Crunch-time for EU directive;http://www.the-scientist.com/article/display/22025/
[3rd March 2004]*linkurl:New clinical trials initiative steps closer;http://www.the-scientist.com/article/display/20664/
[9th September 2002]*linkurl:EU directive on clinical trials will cost lives;http://www.the-scientist.com/article/display/19232/
[23rd October 2000]

Meet the Author

Jef Akst

Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

View Full Profile

EU trial rules stall research

The Scientist ARCHIVES

Become a Member of

Meet the Author

Jef Akst

Related Research Resources

What Is the Amniotic Fluid Composed of?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Skip the Wait for Protein Stability Data with Aunty

Products

Product News

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform